Centogene NV
NASDAQ:CNTG
Relative Value
The Relative Value of one CNTG stock under the Base Case scenario is 6.2021 USD. Compared to the current market price of 0.4889 USD, Centogene NV is Undervalued by 92%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
CNTG Competitors Multiples
Centogene NV Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
DE |
Centogene NV
NASDAQ:CNTG
|
13.6m USD | 0.2 | -0.2 | -1.1 | -0.9 | ||
US |
Abbvie Inc
NYSE:ABBV
|
281.9B USD | 5.2 | 58.5 | 12.7 | 19.4 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
144.5B USD | 5.1 | 21.5 | 16.1 | 24.1 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
102.4B USD | 10.4 | 28.3 | 22.6 | 23.7 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
96.6B USD | 7.4 | 24.4 | 16.1 | 17.7 | ||
AU |
CSL Ltd
ASX:CSL
|
132B AUD | 6.1 | 34.9 | 21.2 | 26.2 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
81.5B USD | 3 | 14.4 | 7.9 | 10.2 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
41.2B USD | 6 | -8.7 | -9.2 | -7.8 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
30.3B USD | 3.1 | 26.1 | 14.2 | 17.6 | ||
KR |
Celltrion Inc
KRX:068270
|
36.6T KRW | 16.8 | 68.3 | 41.9 | 57.7 |